BD announces FDA approval for its Check-Points CPO assay for the BD MAX fully automated molecular platform. Created to help manage antibiotic-resistant hospital-acquired infections (HAIs), BD’s molecular panel can detect 5 of the most common carbapenemase genes in 2.5 hours. This detection assay is an addition to BD’s portfolio dedicated to reducing transmission and outbreak of deadly pathogens, allowing hospitals and clinical laboratories to offer efficient time to result, and enabling immediate deployment of control measures and treatment.

BD